RAPT Therapeutics Beheer

Beheer criteriumcontroles 2/4

De CEO RAPT Therapeutics is Brian Wong, benoemd in Aug2015, heeft een ambtstermijn van 9.25 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 6.59M, bestaande uit 9.2% salaris en 90.8% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 1.41% van de aandelen van het bedrijf, ter waarde $ 1.10M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 4.8 jaar en 7.5 jaar.

Belangrijke informatie

Brian Wong

Algemeen directeur

US$6.6m

Totale compensatie

Percentage CEO-salaris	9.2%
Dienstverband CEO	9.3yrs
Eigendom CEO	1.4%
Management gemiddelde ambtstermijn	4.8yrs
Gemiddelde ambtstermijn bestuur	7.5yrs

Recente managementupdates

Recent updates

RAPT: CCR4 Inhibition Presses On For Now With Oncology Focus

Jul 24

Companies Like RAPT Therapeutics (NASDAQ:RAPT) Could Be Quite Risky

Jun 13

RAPT Therapeutics: Dip Following FDA Clinical Hold Creates Asymmetric Opportunity

May 20

RAPT Therapeutics (NASDAQ:RAPT) Is In A Good Position To Deliver On Growth Plans

Jan 25

RAPT Therapeutics (NASDAQ:RAPT) Is In A Good Position To Deliver On Growth Plans

Oct 15

RAPT Therapeutics (RAPT) skyrockets 100% on positive RPT193 data in early-stage atopic dermatitis study

Jun 14

RAPT Therapeutics (NASDAQ:RAPT) Is In A Good Position To Deliver On Growth Plans

Jun 08

Should You Take Comfort From Insider Transactions At RAPT Therapeutics, Inc. (NASDAQ:RAPT)?

Mar 15

We Think RAPT Therapeutics (NASDAQ:RAPT) Can Easily Afford To Drive Business Growth

Feb 15

RAPT Therapeutics' (NASDAQ:RAPT) Stock Price Has Reduced 56% In The Past Year

Jan 18

RAPT Therapeutics: Interesting Asset, But Doubtful History And Bad Market Reaction

Jan 08

Here's What RAPT Therapeutics, Inc.'s (NASDAQ:RAPT) Shareholder Ownership Structure Looks Like

Dec 21

The Independent Chairman of the Board of RAPT Therapeutics, Inc. (NASDAQ:RAPT), William Rieflin, Just Bought 12% More Shares

Nov 23

Earnings Beat: RAPT Therapeutics, Inc. (NASDAQ:RAPT) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts

Nov 19

RAPT Therapeutics tumbles 25% despite promising FLX475 data in multiple cancers

Nov 16

Analyse CEO-vergoeding

Hoe is Brian Wong's beloning veranderd ten opzichte van RAPT Therapeutics's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Jun 30 2024	n/a	n/a	-US$120m
Mar 31 2024	n/a	n/a	-US$118m
Dec 31 2023	US$7m	US$605k	-US$117m
Sep 30 2023	n/a	n/a	-US$109m
Jun 30 2023	n/a	n/a	-US$99m
Mar 31 2023	n/a	n/a	-US$93m
Dec 31 2022	US$5m	US$580k	-US$84m
Sep 30 2022	n/a	n/a	-US$79m
Jun 30 2022	n/a	n/a	-US$76m
Mar 31 2022	n/a	n/a	-US$73m
Dec 31 2021	US$3m	US$540k	-US$69m
Sep 30 2021	n/a	n/a	-US$64m
Jun 30 2021	n/a	n/a	-US$60m
Mar 31 2021	n/a	n/a	-US$56m
Dec 31 2020	US$4m	US$500k	-US$53m
Sep 30 2020	n/a	n/a	-US$53m
Jun 30 2020	n/a	n/a	-US$49m
Mar 31 2020	n/a	n/a	-US$47m
Dec 31 2019	US$2m	US$447k	-US$43m
Sep 30 2019	n/a	n/a	-US$39m
Jun 30 2019	n/a	n/a	-US$40m
Mar 31 2019	n/a	n/a	-US$37m
Dec 31 2018	US$1m	US$425k	-US$36m

Compensatie versus markt: De totale vergoeding ($USD 6.59M ) Brian } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 655.02K ).

Compensatie versus inkomsten: De vergoeding van Brian is gestegen terwijl het bedrijf verliesgevend is.

CEO

Brian Wong (52 yo)

9.3yrs

Tenure

US$6,591,617

Compensatie

Dr. Brian Russell Wong, M.D., Ph.D. serves as Venture Partner at The Column Group, LLC since joining the firm in 2022. He has been Chief Executive Officer and Director at RAPT Therapeutics, Inc. since Augu...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Brian Wong	CEO, President & Director	9.3yrs	US$6.59m	1.41% $ 1.1m
Rodney K. Young	CFO, Principal Accounting Officer & Secretary	4.9yrs	US$2.18m	0.034% $ 26.2k
William Ho	Chief Medical Officer	9.5yrs	US$1.90m	0.045% $ 35.1k
Steve Young	Vice President of Technology	no data	geen gegevens	geen gegevens
Dirk Brockstedt	Chief Scientific Officer	5.4yrs	US$1.48m	0.074% $ 57.6k
Michael Listgarten	General Counsel	1.8yrs	geen gegevens	geen gegevens
Gwen Carscadden	Chief Human Resources Officer	2.5yrs	geen gegevens	geen gegevens
Paul Kassner	Senior Vice President of Quantitative & Computational Biology	4.7yrs	geen gegevens	geen gegevens
David Wustrow	Senior Vice President of Drug Discovery & Preclinical Development	5.8yrs	geen gegevens	geen gegevens
Jennifer Nicholson	Senior Vice President of Regulatory Affairs & Quality Assurance	2.2yrs	geen gegevens	geen gegevens
Nipun Davar	Senior Vice President of Technical Operations	less than a year	geen gegevens	geen gegevens

4.8yrs

Gemiddelde duur

57.5yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van RAPT wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.8 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Brian Wong	CEO, President & Director	9.3yrs	US$6.59m	1.41% $ 1.1m
William Rieflin	Independent Chairman of the Board	9.5yrs	US$300.28k	0.27% $ 211.2k
Mary Gray	Independent Director	4.9yrs	US$277.78k	0% $ 0
Andrew Pardoll	Member of Scientific Advisory Board	7.5yrs	geen gegevens	geen gegevens
Philip Greenberg	Member of Scientific Advisory Board	7.5yrs	geen gegevens	geen gegevens
Alexander Rudensky	Chairman of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Antoni Ribas	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Scott Antonia	Member of Scientific Advisory Board	7.2yrs	geen gegevens	geen gegevens
Emma Guttman-Yassky	Member of Scientific Advisory Board	5.3yrs	geen gegevens	geen gegevens
Michael Giordano	Independent Director	6.8yrs	US$267.78k	0% $ 0
Linda Kozick	Independent Director	7.9yrs	US$260.78k	0% $ 0
Robert Zamboni	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens

7.5yrs

Gemiddelde duur

65yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van RAPT wordt beschouwd als ervaren (gemiddelde ambtstermijn 7.5 jaar).

RAPT Therapeutics Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

RAPT Therapeutics, Inc., Annual General Meeting, May 22, 2024

RAPT Therapeutics, Inc. Appoints Nipun Davar as Senior Vice President of Technical Operations

Chief Medical Officer notifies of intention to sell stock

Insider recently bought US$98k worth of stock

Chief Medical Officer notifies of intention to sell stock

Chief Medical Officer notifies of intention to sell stock

Recent updates

Rapt Therapeutics Approves Reduction to Their Workforce

RAPT: CCR4 Inhibition Presses On For Now With Oncology Focus

Companies Like RAPT Therapeutics (NASDAQ:RAPT) Could Be Quite Risky

RAPT Therapeutics: Dip Following FDA Clinical Hold Creates Asymmetric Opportunity

Price target decreased by 18% to US$18.14

RAPT Therapeutics Announces Promising Results from Phase 2 Trial of Tivumecirnon in Combination with Anti-PD-1 Immunotherapy in CPI-Experienced Head and Neck Cancer Patients

RAPT Therapeutics, Inc., Annual General Meeting, May 22, 2024

New minor risk - Shareholder dilution

Price target decreased by 21% to US$33.63

Is RAPT Therapeutics (NASDAQ:RAPT) In A Good Position To Invest In Growth?

RAPT Therapeutics, Inc. Announces FDA Verbally Notifies Clinical Hold on its Phase 2b Trial of Zelnecirnon (RPT193) in Atopic Dermatitis and its Phase 2a Trial in Asthma

New major risk - Revenue and earnings growth

RAPT Therapeutics, Inc. Appoints Nipun Davar as Senior Vice President of Technical Operations

RAPT Therapeutics, Inc. Announces Publication of Phase 1a/1b Clinical Trial of Zelnecirnon (RPT193) to Treat Atopic Dermatitis in Allergy

RAPT Therapeutics, Inc. Announces Publication of Phase 1a/1b Clinical Trial of Zelnecirnon (RPT193) to Treat Atopic Dermatitis in Allergy

New major risk - Revenue and earnings growth

New minor risk - Share price stability

RAPT Therapeutics, Inc. Announces Positive Data, Including Objective Response Rates and Progression-Free Survival, from its Phase 2 Trial of FLX475 in Combination with a Checkpoint Inhibitor in Patients with Advanced NSCLC

New major risk - Revenue and earnings growth

We Think RAPT Therapeutics (NASDAQ:RAPT) Can Afford To Drive Business Growth

First quarter 2023 earnings released: US$0.77 loss per share (vs US$0.69 loss in 1Q 2022)

We Think RAPT Therapeutics (NASDAQ:RAPT) Can Afford To Drive Business Growth

Chief Medical Officer notifies of intention to sell stock

Insider recently bought US$98k worth of stock

Full year 2022 earnings: EPS in line with expectations, revenues disappoint

Chief Medical Officer notifies of intention to sell stock

We're Hopeful That RAPT Therapeutics (NASDAQ:RAPT) Will Use Its Cash Wisely

Chief Medical Officer notifies of intention to sell stock

Chief Medical Officer notifies of intention to sell stock

Insufficient new directors

RAPT Therapeutics Presents Update from its Phase 1/2 Clinical Trial for FLX475 as Monotherapy and in Combination with Pembrolizumab in Patients with Advanced Cancer

Chief Medical Officer notifies of intention to sell stock

Consensus forecasts updated

Third quarter 2022 earnings released: US$0.63 loss per share (vs US$0.63 loss in 3Q 2021)

Third quarter 2022 earnings released: US$0.63 loss per share (vs US$0.63 loss in 3Q 2021)

Chief Medical Officer notifies of intention to sell stock

We're Hopeful That RAPT Therapeutics (NASDAQ:RAPT) Will Use Its Cash Wisely

RAPT Therapeutics Announces Executive Changes

Consensus forecasts updated

Consensus forecasts updated

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Price target decreased to US$50.29

RAPT Therapeutics, Inc. announced that it expects to receive $49.9996 million in funding from Redmile Group, LLC

Price target decreased to US$53.00

RAPT Therapeutics Announces Initiation of Phase 2B Trial of Rpt193 in Patients with Moderate-To-Severe Atopic Dermatitis

Consensus forecasts updated

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Insider recently bought US$77k worth of stock

RAPT Therapeutics, Inc. Announces Appointment of Gwen Carscadden as Chief Human Resources Officer

RAPT Therapeutics, Inc., Annual General Meeting, May 25, 2022

Consensus forecasts updated

Consensus forecasts updated

RAPT Therapeutics Announces Biomarker Data from Phase 1b Trial of RPT193 Consistent with Disease Modification in Atopic Dermatitis

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

RAPT Therapeutics (NASDAQ:RAPT) Is In A Good Position To Deliver On Growth Plans

Chief Scientific Officer exercised options and sold US$69k worth of stock

Chief Scientific Officer exercised options and sold US$65k worth of stock

Third quarter 2021 earnings released: US$0.63 loss per share (vs US$0.60 loss in 3Q 2020)

RAPT Therapeutics (NASDAQ:RAPT) Is In A Good Position To Deliver On Growth Plans

Chief Scientific Officer exercised options and sold US$65k worth of stock

Insider recently sold US$424k worth of stock

Chief Scientific Officer exercised options and sold US$78k worth of stock

Price target increased to US$62.14

Member of Scientific Advisory Board recently sold US$1.2m worth of stock

Insider recently sold US$1.1m worth of stock

Chief Scientific Officer exercised options and sold US$66k worth of stock

Second quarter 2021 earnings released: US$0.63 loss per share (vs US$0.51 loss in 2Q 2020)

Consensus forecasts updated

Chief Medical Officer exercised options to buy US$256k worth of stock.